Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/ emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II)

HIV Clinical Trials

Volumn 10, Issue 3, 2009, Pages 160-167

  Parks, David A ^a   Jennings, H Clay ^a   Taylor, Christopher ^a   Pakes, Gary E ^b   Acosta, Edward P ^c  

^a Central West Clinical Research   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Emtricitabine; Fosamprenavir; HIV infection; Ritonavir; Tenofovir disoproxil fumarate

Indexed keywords

AMPRENAVIR PHOSPHATE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CARBAMATES; CD4 LYMPHOCYTE COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PHOSPHORIC ACID ESTERS; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 69249138237     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1003-160     Document Type: Article

References (28)

1. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45: 137-168.
2. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate. Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595-612.
3. Bang LM, Scott LJ. Emtricitabine. An antiretroviral agent for HIV infection. Drugs. 2003;63:2413-2424.
4. Cooper CL, van Heeswijk RPG, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36:1585-1592.
5. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ ritonavir versus twice-daily nelfi navir in naive HIV-1- infected patients. AIDS. 2004;18:1529-1537.
6. Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5(5):1-10.
7. DeJesus E, Sloan L, Sension M, et al. 96-week efficacy/safety data comparing two doses of ritonavir (/r) to boost once-daily (QD) fosamprenavir (FPV), used in combination with abacavir (ABC)/lamivudine (3TC). In : Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 48th Annual Meeting/Infectious Diseases Society of America/46th Annual Meeting; October 25-28, 2008; Washington, DC. Abstract/Poster H-1246.
8. Hsu R, Walker-Reed K, Acosta E. Fosamprenavir (FPV) with low-dose ritonavir (RTV) once-daily (QD) in HIV-infected subjects. In: Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22, 2006; Lisbon, Portugal. Abstract/poster 71.
9. Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2007;51:560-565.
10. min) and inhibitory quotients (IQ), at steady-state, in plasma and lymphocytes of HIV infected patients receiving different dosage regimens. In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30 2005; Quebec City (QC). Abstract 5, Poster 1.5.
11. DeWit S, Poll B, Necsoi C, Clumeck N. Fosamprenavir boosted with a single 100 mg capsule of ritonavir as part of a once daily first line regimen in naïve patients. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, United Kingdom. Abstract/poster P17.
12. min levels in patients receiving once-daily fosamprenavir in combination with either 100 or 200 mg ritonavir. In: Program and abstracts from Congrès P2T Physiology, Pharmacology and Thérapeutics; April 2007; Toulouse, France. Abstract 216.
13. FDA approves administration of LEXIVA with lower dose of "boosting" medication ritonavir [press release]. October 12, 2007. Availableat: http://us.gsk.com/ControllerServlet?appId= 4&pageId= 402&newsid=1158.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed February 3, 2009.
15. Parks DA, Jennings HC, Taylor CW, et al. Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. AIDS. 2007;21:1373-1375.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
17. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother. 2002;46:746-754.
18. Kurowski M. Influence of 50 mg, 100 mg, and 200 mg ritonavir (RTV) on the pharmacokinetics (PK) of amprenavir (APV) after multiple doses in healthy volunteers for once daily (QD) and twice daily (BID) regimens. In: Program and abstracts of the First International AIDS Society Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires, Argentina. Abstract 351.
19. Kilby JM, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med. 2002;3:97-104.
20. Shelton MJ, Wire MB, Lou Y, et al. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chemother. 2006;50:928-934.
21. Luber A, Slowinski D, Andrews M, et al. Steady-state pharmacokinetics (PK) of tenofovir (TDF) and fosamprenavir (FPV) after once daily (QD) TDF with unboosted or ritonavir (R)-boosted twice daily (BID) FPV in healthy volunteers. In: Program and abstracts of the 8th International Congress of Drug Therapy and HIV Infection; November 12-16, 2006; Glasgow, UK. Abstract/Poster P274.
22. Kurowski M, Walli RK, Breske A, et al. Fosamprenavir/ ritonavir does not affect amprenavir pharmacokinetics: no effect of tenofovir. AIDS. 2007;21:1368-1370.
23. DeJesus E, Lamarca A, Sension M, et al. The CONTEXT study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure 24-week results. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, MA. Abstract/presentation 178.
24. Zong J, Chittick GE, Wang LH, Hui J, Begley JA, Blum MR. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol. 2007;47:877-889.
25. Wang LH, Begley J, St Claire RL, et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20:1173-1182.
26. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodefi ciency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
27. Ramanathan S, Shen G, Cheng A, et al. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr. 2007;45:274-279.
28. Ray AS, Tong L, Robinson KL, et al. Role of intestinal absorption in increased tenofovir exposure when tenofovir disoproxil fumarate is co-administered with atazanavir or lopinavir/ritonavir. In: Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22, 2006; Lisbon, Portugal. Abstract 49.